Physician profile
Majd Hakim
NPI 1598871378
$141,805.45
in general payments reported to CMS, 2019-2025
40 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $13K · 2021: $15K · 2022: $28K · 2023: $9,666 · 2024: $15K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $3,861 · Travel and Lodging: $1,219 · Education: $65.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,515.75 |
| Food and Beverage | $3,860.75 |
| Travel and Lodging | $1,219.01 |
| Education | $65.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104,376.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $17,407.04 | 2019-2025 | Farxiga |
| Abbvie INC. | $17,400.37 | 2019-2025 | |
| Lilly USA, LLC | $360.51 | 2023-2025 | Mounjaro, Jardiance, Kisunla |
| Amgen INC. | $220.55 | 2023-2025 | Evenity, Prolia, Tepezza |
| Amneal Pharmaceuticals LLC | $164.72 | 2024-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.36 | 2023-2025 | Jardiance |
| Medtronic, INC. | $144.00 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Corcept Therapeutics | $127.51 | 2024-2025 | Korlym |
| Radius Health, INC. | $108.80 | 2024-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $93.02 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Madrigal Pharmaceuticals | $82.02 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $81.44 | 2023-2024 | Tirosint, Licart, Licart |
| Dexcom, INC. | $80.06 | 2023-2024 | Dexcom G6 Transmitter |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $78.35 | 2025 | Yorvipath |
| Insulet Corporation | $77.08 | 2024-2025 | Omnipod |
| Antares Pharma, INC. | $69.40 | 2024-2025 | Xyosted, Tlando |
| Abbott Laboratories | $65.99 | 2023-2025 | Freestyle Libre 3 |
| Tosoh Bioscience, INC. | $62.00 | 2019 | |
| Astellas Pharma US INC | $57.64 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $55.24 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Beta Bionics, INC. | $49.73 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $44.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.24 | 2023-2024 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Rhythm Pharmaceuticals, INC. | $35.14 | 2023-2025 | Imcivree, Imcivree |
| Neurocrine Biosciences, INC. | $30.95 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.70 | 2025 | Evkeeza |
| Chiesi USA, INC. | $26.06 | 2025 | Mycapssa |
| Aimmune Therapeutics, INC. | $24.47 | 2025 | Zenpep |
| Recordati_rare_diseases_inc. | $23.68 | 2023 | Signifor Lar, Isturisa |
| Tactile Systems Technology INC | $20.95 | 2025 | Flexitouch Plus, Nimbl |
| Cequr Corporation | $19.56 | 2023 | Cequr Simplicity |
| Alnylam Pharmaceuticals INC. | $17.35 | 2025 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $17.31 | 2025 | Rexulti |
| Sequel Med Tech, LLC | $17.09 | 2025 | Twiist |
| Seqirus USA INC | $15.76 | 2024 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $15.70 | 2025 | Nexletol |
| Biotronik Nro, INC. | $14.74 | 2024 | Prospera |
| Nevro Corp. | $12.91 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majd Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.